Join the Plaque Psoriasis group to help and get support from people like you.
Plaque Psoriasis News
Psoriasis 101: Causes, Symptoms and Treatments, Explained
MONDAY, July 7, 2025 — Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends signals to your skin cells to grow too fast. N...
Central Adiposity Measures Associated With Psoriasis Risk
TUESDAY, June 3, 2025 – Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a research letter published online May 27 in the...
Psoriasis Tied to Increased Risk for Sleep Disorders
MONDAY, June 2, 2025 – Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according to a study published online May 13 in JEADV ...
Belly Fat Linked To Psoriasis
THURSDAY, May 29, 2025 — Belly flab appears to be a stronger warning sign for psoriasis than fat located elsewhere on the body, a new study says. Fat around the abdomen is more strongly linked to p...
FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body, Zoryve
TUESDAY, May 27, 2025 – The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and...
Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
WESTLAKE VILLAGE, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in imm...
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
WEDNESDAY, May 21, 2025 – For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity...
Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
WEDNESDAY, April 30, 2025 – Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA), according to a study published online March 29 in...
Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis
FRIDAY, Feb. 28, 2025 – For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing initial response, according to a study published...
Childhood Maltreatment May Up Risk for Immune-Mediated Inflammatory Disorders
THURSDAY, Jan. 23, 2025 – On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders (IMIDs), according to a study...
FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...
High Ultraprocessed Food Intake Linked to Active Psoriasis
TUESDAY, Dec. 3, 2024 – High ultraprocessed food (UPF) intake is associated with active psoriasis, according to a research letter published online Nov. 27 in JAMA Dermatology. Laetitia Penso, Ph.D.,...
FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced ...
Ultraprocessed Foods Might Help Trigger Psoriasis
WEDNESDAY, Nov. 27, 2024 – Ultraprocessed foods have been linked to a myriad of health issues, and a new study suggests that the autoimmune skin disease psoriasis might be added to that list....
FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara
RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
Further information
Related condition support groups
Related drug support groups
methylprednisolone, Humira, Enbrel, Stelara, Remicade, Otezla, Cosentyx, Skyrizi, dexamethasone, view more... adalimumab, etanercept, halobetasol, ustekinumab, Cimzia, Taltz